LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Lista de Ações・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Fechado

SetorSaúde

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

Máximo

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	-0.05% downside

Sentimento de Notícias

By Acuity

50%

137 / 345 Ranking em Healthcare

Mirati Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de mai. de 2026, 22:47 UTC

Ações em Alta

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 de mai. de 2026, 22:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 de mai. de 2026, 22:00 UTC

Grandes Movimentos do Mercado

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 de mai. de 2026, 18:09 UTC

Grandes Movimentos do Mercado

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 de mai. de 2026, 16:02 UTC

Ganhos

Grandes Movimentos do Mercado

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 de mai. de 2026, 14:55 UTC

Grandes Movimentos do Mercado

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

16 de mai. de 2026, 16:27 UTC

Aquisições, Fusões, Aquisições de Empresas

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 de mai. de 2026, 08:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de mai. de 2026, 22:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 de mai. de 2026, 21:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 de mai. de 2026, 21:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 de mai. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 de mai. de 2026, 21:16 UTC

Conversa de Mercado

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

15 de mai. de 2026, 20:19 UTC

Ações em Alta

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 de mai. de 2026, 19:41 UTC

Aquisições, Fusões, Aquisições de Empresas

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 de mai. de 2026, 19:35 UTC

Conversa de Mercado

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 de mai. de 2026, 19:33 UTC

Conversa de Mercado

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 de mai. de 2026, 18:35 UTC

Ganhos

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 de mai. de 2026, 17:28 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 de mai. de 2026, 16:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 de mai. de 2026, 16:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

15 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

15 de mai. de 2026, 15:55 UTC

Conversa de Mercado

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 de mai. de 2026, 15:20 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 de mai. de 2026, 15:20 UTC

Conversa de Mercado

Silver Plunges on Inflation Worries -- Market Talk

15 de mai. de 2026, 15:20 UTC

Ganhos

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

Comparação entre Pares

Variação de preço

Mirati Therapeutics Inc Previsão

Preço-alvo

By TipRanks

-0.05% parte inferior

Previsão para 12 meses

Média 58.67 USD -0.05%

Máximo 59 USD

Mínimo 58 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Mirati Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Mirati Therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

137 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

EBITDA

Resultado Operacional

Sobre Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.